Technology | May 25, 2011

Boston Scientific Launches 2.25 mm Promus Coronary Stent

May 25, 2011 – Boston Scientific Corp. today announced it received approval from the U.S. Food and Drug Administration (FDA) to market its 2.25 mm Promus everolimus-eluting coronary stent system for use in vessels as small as 2.25 mm in diameter. The company plans to immediately launch the product in the United States.

The Promus stent features a thin-strut, open-cell design to allow for excellent flexibility and conformability in the vessel. The low-profile stent and catheter tip help enhance deliverability, especially in small vessels. The Promus stent is supported by the SPIRIT clinical trial program, which demonstrates that the controlled release of everolimus results in low levels of late loss and a strong safety profile. The addition of this stent expands the available size matrix of Boston Scientific's Promus stent portfolio to include diameters from 2.25 to 4 mm and lengths from 8 to 28 mm.

"The Promus stent has demonstrated outstanding deliverability, low late loss and excellent safety in numerous clinical trials and extensive real-world practice," said Dean J. Kereiakes, M.D., FACC, medical director, The Christ Hospital Heart and Vascular Center and The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, and professor of clinical medicine, Ohio State University. "These benefits make the Promus 2.25 mm stent an attractive option for U.S. physicians treating patients with small vessels."

Data from clinical studies have shown that an estimated 10 percent of patients undergoing percutaneous coronary interventions have small vessels (less than 2.5 mm). The 2.25 mm Promus stent joins the 2.25 mm Ion paclitaxel-eluting platinum chromium stent as the company's approved drug-eluting stenting options for small vessels.

The Promus stent is a private-labeled Xience V everolimus-eluting coronary stent system manufactured by Abbott and distributed by Boston Scientific. The stent is sold under the Promus name as part of a 2006 agreement from when Abbott purchased the Xience stent technology from Boston.

For more information: www.bostonscientific.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Overlay Init